Skip to main content
SpringerLink
Log in

Role of PET/CT in Pediatric Malignancy

  • Chapter
  • First Online:
Basic Science of PET Imaging

  • 3129 Accesses

Abstract

Positron emission tomography (PET)/computed tomography (CT) is emerging as an important noninvasive imaging modality for assessing a wide variety of malignancies in both adults and children. However, a different approach may be needed in children than that of adults due to vulnerability of children to radiation, different types of malignancies in pediatric population comparing with adults, and special technical issues and pitfalls in pediatric PET/CT imaging. In this chapter, we discuss special considerations in pediatric PET/CT imaging and explore the use of FDG-PET in pediatric malignancies, including lymphomas, sympathetic nervous system tumors, bone and soft tissue sarcomas, neuroblastomas, and the less-common tumors, such as thyroid cancers, Wilms’ tumors, and hepatoblastomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Davidoff AM. Pediatric oncology. Semin Pediatr Surg. 2010;19(3):225–33.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  3. Steliarova-Foucher E, et al. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457–67.

    Article  PubMed  Google Scholar 

  4. Steliarova-Foucher E, et al. Trends in childhood cancer incidence in Europe, 1970–99. Lancet. 2005;365(9477):2088.

    Article  PubMed  Google Scholar 

  5. SEER NCI. The Survival, Epidemiology, and End Result Program: SEER stats fact sheet: thyroid cancer. National Cancer Institute. 2014. http://seer.cancer.gov/statfacts/html/thyro.html.

  6. Uslu L, et al. Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med. 2015;56(2):274–86.

    Article  PubMed  CAS  Google Scholar 

  7. Gulyas B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56(2):173–90.

    CAS  PubMed  Google Scholar 

  8. Persson M, et al. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol. 2012;39(4):560–9.

    Article  CAS  PubMed  Google Scholar 

  9. Fernandes E, et al. Positron emitting tracers in pre-clinical drug development. Curr Radiopharm. 2012;5(2):90–8.

    Article  CAS  PubMed  Google Scholar 

  10. Prezzi D, Khan A, Goh V. Perfusion CT imaging of treatment response in oncology. Eur J Radiol. 2015;84:2380–5.

    Article  PubMed  Google Scholar 

  11. Coursey CA, et al. Dual-energy multidetector CT: how does it work, what can it tell us, and when can we use it in abdominopelvic imaging? Radiographics. 2010;30(4):1037–55.

    Article  PubMed  Google Scholar 

  12. Lee YH, et al. Spectral parametric segmentation of contrast-enhanced dual-energy CT to detect bone metastasis: feasibility sensitivity study using whole-body bone scintigraphy. Acta Radiol. 2015;56(4):458–64.

    Article  PubMed  Google Scholar 

  13. Brady SL, Shulkin BL. Ultralow dose computed tomography attenuation correction for pediatric PET CT using adaptive statistical iterative reconstruction. Med Phys. 2015;42(2):558–66.

    Article  PubMed  Google Scholar 

  14. Schafer JF, et al. Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology. 2014;273(1):220–31.

    Article  PubMed  Google Scholar 

  15. Dunkl V, et al. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med. 2015;56(1):88–92.

    Article  CAS  PubMed  Google Scholar 

  16. Misch M, et al. (18)F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. Childs Nerv Syst. 2015;31(2):261–7.

    Article  PubMed  Google Scholar 

  17. Fraioli F, et al. 18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors. Clin Nucl Med. 2015;40(1):e40–5.

    Article  PubMed  Google Scholar 

  18. Kurihara Y, et al. MRI of pulmonary nodules. AJR Am J Roentgenol. 2014;202(3):W210–6.

    Article  PubMed  Google Scholar 

  19. Loeffelbein DJ, et al. PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg. 2012;70(2):473–83.

    Article  PubMed  Google Scholar 

  20. Buckwalter KA, Lin C, Ford JM. Managing postoperative artifacts on computed tomography and magnetic resonance imaging. Semin Musculoskelet Radiol. 2011;15(4):309–19.

    Article  PubMed  Google Scholar 

  21. Hendee WR, O’Connor MK. Radiation risks of medical imaging: separating fact from fantasy. Radiology. 2012;264(2):312–21.

    Article  PubMed  Google Scholar 

  22. Dobyns BM, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974;38(6):976–98.

    Article  CAS  PubMed  Google Scholar 

  23. Ron E, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280(4):347–55.

    Article  CAS  PubMed  Google Scholar 

  24. Fahey FH, Treves ST, Adelstein SJ. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med. 2011;52(8):1240–51.

    PubMed  Google Scholar 

  25. Preston DL, et al. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950–1997. Radiat Res. 2003;160(4):381–407.

    Article  CAS  PubMed  Google Scholar 

  26. Turner HC, et al. Effect of dose rate on residual gamma-H2AX levels and frequency of micronuclei in X-irradiated mouse lymphocytes. Radiat Res. 2015;183(3):315–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Pouliliou S, Koukourakis MI. Gamma histone 2AX (gamma-H2AX) as a predictive tool in radiation oncology. Biomarkers. 2014;19(3):167–80.

    Article  CAS  PubMed  Google Scholar 

  28. Huda W. Radiation risks: what is to be done? AJR Am J Roentgenol. 2015;204(1):124–7.

    Article  PubMed  Google Scholar 

  29. Ng AK, et al. Secondary malignancies across the age spectrum. Semin Radiat Oncol. 2010;20(1):67–78.

    Article  PubMed  Google Scholar 

  30. Fridlich R, et al. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication. DNA Repair (Amst). 2015;30:11–20.

    Article  CAS  Google Scholar 

  31. Drooger JC, et al. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. Cancer Treat Rev. 2015;41(2):187–96.

    Article  CAS  PubMed  Google Scholar 

  32. Piechowiak EI, et al. Intravenous iodinated contrast agents amplify DNA radiation damage at CT. Radiology. 2015;275:692–7. doi:10.1148/radiol.14132478.

    Article  PubMed  Google Scholar 

  33. Lacaille H, et al. Comparison of the deleterious effects of binge drinking-like alcohol exposure in adolescent and adult mice. J Neurochem. 2015;132(6):629–41.

    Article  CAS  PubMed  Google Scholar 

  34. Heydenreich J, et al. Reliability of a fully automated interpretation of gamma -H2AX foci in lymphocytes of moderately trained subjects under resting conditions. J Nutr Metab. 2014;2014:478324.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Gelfand MJ. Dose reduction in pediatric hybrid and planar imaging. Q J Nucl Med Mol Imaging. 2010;54(4):379–88.

    CAS  PubMed  Google Scholar 

  36. Accorsi R, Karp JS, Surti S. Improved dose regimen in pediatric PET. J Nucl Med. 2010;51(2):293–300.

    Article  PubMed  Google Scholar 

  37. Lassmann M, et al. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging. 2007;34(5):796–8.

    Article  CAS  PubMed  Google Scholar 

  38. Gelfand MJ, et al. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011;52(2):318–22.

    Article  PubMed  Google Scholar 

  39. American Academy of P, et al. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics. 2006;118(6):2587–602.

    Article  Google Scholar 

  40. Arlachov Y, Ganatra RH. Sedation/anaesthesia in paediatric radiology. Br J Radiol. 2012;85(1019):e1018–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Delbeke D, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885–95.

    PubMed  Google Scholar 

  42. Shen G, et al. Potential performance of dual-time-point 18F-FDG PET/CT compared with single-time-point imaging for differential diagnosis of metastatic lymph nodes: a meta-analysis. Nucl Med Commun. 2014;35(10):1003–10.

    Article  CAS  PubMed  Google Scholar 

  43. Shen G, et al. Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis. Acta Radiol. 2015;56:681–7.

    Article  PubMed  Google Scholar 

  44. Costantini DL, et al. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors. AJR Am J Roentgenol. 2013;200(2):408–13.

    Article  PubMed  Google Scholar 

  45. Zukotynski KA, et al. Constant ambient temperature of 24 degrees C significantly reduces FDG uptake by brown adipose tissue in children scanned during the winter. Eur J Nucl Med Mol Imaging. 2009;36(4):602–6.

    Article  PubMed  Google Scholar 

  46. Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics. 2009;29(5):1467–86.

    Article  PubMed  Google Scholar 

  47. Keyes Jr JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36(10):1836–9.

    PubMed  Google Scholar 

  48. Ghanem MA, Kazim NA, Elgazzar AH. Impact of obesity on nuclear medicine imaging. J Nucl Med Technol. 2011;39(1):40–50.

    Article  PubMed  Google Scholar 

  49. Krak NC, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32(3):294–301.

    Article  PubMed  Google Scholar 

  50. Boellaard R, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45(9):1519–27.

    PubMed  Google Scholar 

  51. Bemben MG, et al. Age-related variability in body composition methods for assessment of percent fat and fat-free mass in men aged 20–74 years. Age Ageing. 1998;27(2):147–53.

    Article  CAS  PubMed  Google Scholar 

  52. Nakahara T, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol. 2001;74(885):821–4.

    Article  CAS  PubMed  Google Scholar 

  53. Francis IR, et al. The thymus: reexamination of age-related changes in size and shape. AJR Am J Roentgenol. 1985;145(2):249–54.

    Article  CAS  PubMed  Google Scholar 

  54. Brink I, et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001;42(4):591–5.

    CAS  PubMed  Google Scholar 

  55. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics. 2004;24(6):1611–6.

    Article  PubMed  Google Scholar 

  56. Sasaki M, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40(10):1595–601.

    CAS  PubMed  Google Scholar 

  57. Heusner TA, et al. Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging. 2009;36(9):1397–406.

    Article  PubMed  Google Scholar 

  58. Elstrom RL, et al. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin’s lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma. 2004;5(1):62–4.

    Article  PubMed  Google Scholar 

  59. Knopp MV, et al. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol. 1996;23(6):845–9.

    Article  CAS  PubMed  Google Scholar 

  60. Trout AT, et al. Optimizing the interval between G-CSF therapy and F-18 FDG PET imaging in children and young adults receiving chemotherapy for sarcoma. Pediatr Radiol. 2015;45:1001–6.

    Article  PubMed  Google Scholar 

  61. Aflalo-Hazan V, et al. Increased FDG uptake by bone marrow in major beta-thalassemia. Clin Nucl Med. 2005;30(11):754–5.

    Article  CAS  PubMed  Google Scholar 

  62. Plantade A, et al. Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. Clin Nucl Med. 2003;28(9):771–2.

    Article  PubMed  Google Scholar 

  63. Hong TS, et al. Brown adipose tissue 18F-FDG uptake in pediatric PET/CT imaging. Pediatr Radiol. 2011;41(6):759–68.

    Article  PubMed  Google Scholar 

  64. Lin EC, Alavi A. PET and PET/CT: a clinical guide. 2nd ed. New York: Thieme Medical Publishers Inc.; 2009.

    Google Scholar 

  65. Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med. 2008;33(12):894–5.

    Article  PubMed  Google Scholar 

  66. Even-Sapir E, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272–8.

    PubMed  Google Scholar 

  67. Segall G, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51(11):1813–20.

    Article  PubMed  Google Scholar 

  68. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49 Suppl 2:64S–80.

    Article  CAS  PubMed  Google Scholar 

  69. Buck AK, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32(5):525–33.

    Article  PubMed  Google Scholar 

  70. Everitt S, et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):1098–104.

    Article  PubMed  Google Scholar 

  71. Yamamoto Y, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34(10):1610–6.

    Article  CAS  PubMed  Google Scholar 

  72. Yap CS, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129(2):393–401.

    Article  PubMed  Google Scholar 

  73. Kameyama R, et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009;36(3):382–8.

    Article  PubMed  Google Scholar 

  74. Yamamoto Y, et al. Detection of colorectal cancer using 18F-FLT PET: comparison with 18F-FDG PET. Nucl Med Commun. 2009;30:841–5.

    Article  PubMed  Google Scholar 

  75. Cobben DC, et al. 3′-18F-fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med. 2003;44(12):1927–32.

    CAS  PubMed  Google Scholar 

  76. Buck AK, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66(22):11055–61.

    Article  CAS  PubMed  Google Scholar 

  77. Herrmann K, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13(12):3552–8.

    Article  CAS  PubMed  Google Scholar 

  78. Kenny L, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34(9):1339–47.

    Article  PubMed  Google Scholar 

  79. Pio BS, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8(1):36–42.

    Article  PubMed  Google Scholar 

  80. Buck AK, et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res. 2008;14(10):2970–7.

    Article  CAS  PubMed  Google Scholar 

  81. Choi SJ, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32(6):653–9.

    Article  PubMed  Google Scholar 

  82. Gilles R, et al. (18)F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases. Nucl Med Commun. 2010;31(6):482–7.

    PubMed  Google Scholar 

  83. Hatakeyama T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35(11):2009–17.

    Article  CAS  PubMed  Google Scholar 

  84. Saga T, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006;31(12):774–80.

    Article  PubMed  Google Scholar 

  85. Tripathi M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34(12):878–83.

    Article  PubMed  Google Scholar 

  86. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol. 2006;8(3):141–50.

    Article  PubMed  Google Scholar 

  87. Shields AF, et al. Imaging proliferation in vivo with FLT and positron emission tomography. Nat Med. 1998;4(11):1334–6.

    Article  CAS  PubMed  Google Scholar 

  88. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–39.

    Article  CAS  PubMed  Google Scholar 

  89. Harrison LB, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7(6):492–508.

    Article  PubMed  Google Scholar 

  90. Molls M, et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol. 1998;174 Suppl 4:13–6.

    PubMed  Google Scholar 

  91. Hockel M, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56(19):4509–15.

    CAS  PubMed  Google Scholar 

  92. Hockel M, et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6(1):3–9.

    Article  PubMed  Google Scholar 

  93. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003;423(6940):593–5.

    Article  CAS  PubMed  Google Scholar 

  94. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 1997;39(4):361–6.

    Article  CAS  PubMed  Google Scholar 

  95. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res. 2003;9(15):5714–20.

    CAS  PubMed  Google Scholar 

  96. Beck R, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48(6):973–80.

    Article  CAS  PubMed  Google Scholar 

  97. von Pawel J, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 2000;18(6):1351–9.

    Google Scholar 

  98. Brizel DM, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53(2):113–7.

    Article  CAS  PubMed  Google Scholar 

  99. Grosu AL, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):541–51.

    Article  CAS  PubMed  Google Scholar 

  100. O’Tuama LA, et al. Two-phase [11C]L-methionine PET in childhood brain tumors. Pediatr Neurol. 1990;6(3):163–70.

    Article  PubMed  Google Scholar 

  101. Utriainen M, et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer. 2002;95(6):1376–86.

    Article  PubMed  Google Scholar 

  102. Virgolini I, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.

    Article  PubMed  Google Scholar 

  103. Shulkin BL, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37(1):16–21.

    CAS  PubMed  Google Scholar 

  104. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med. 1999;43(3):217–23.

    CAS  PubMed  Google Scholar 

  105. Hoegerle S, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002;222(2):507–12.

    Article  PubMed  Google Scholar 

  106. deKemp RA, Nahmias C. Attenuation correction in PET using single photon transmission measurement. Med Phys. 1994;21(6):771–8.

    Article  CAS  PubMed  Google Scholar 

  107. Biermann M, et al. Is there a role for PET-CT and SPECT-CT in pediatric oncology? Acta Radiol. 2013;54(9):1037–45.

    Article  PubMed  Google Scholar 

  108. Srinivasan M, Bhaskar S, Carlson DW. Variation in procedural sedation practices among Children’s Hospitals. Hosp Pediatr. 2015;5(3):148–53.

    Article  PubMed  Google Scholar 

  109. Martinez-Moller A, Nekolla SG. Attenuation correction for PET/MR: problems, novel approaches and practical solutions. Z Med Phys. 2012;22(4):299–310.

    Article  PubMed  Google Scholar 

  110. Roy S, et al. PET attenuation correction using synthetic CT from ultrashort echo-time MR imaging. J Nucl Med. 2014;55(12):2071–7.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Berker Y, Kiessling F, Schulz V. Scattered PET data for attenuation-map reconstruction in PET/MRI. Med Phys. 2014;41(10):102502.

    Article  PubMed  CAS  Google Scholar 

  112. Yip S, et al. Sensitivity study of voxel-based PET image comparison to image registration algorithms. Med Phys. 2014;41(11):111714.

    Article  PubMed  Google Scholar 

  113. Kinney H, Faix R, Brazy J. The fetal alcohol syndrome and neuroblastoma. Pediatrics. 1980;66(1):130–2.

    CAS  PubMed  Google Scholar 

  114. Kramer S, et al. Medical and drug risk factors associated with neuroblastoma: a case–control study. J Natl Cancer Inst. 1987;78(5):797–804.

    CAS  PubMed  Google Scholar 

  115. Michalek AM, et al. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol. 1996;143(10):996–1001.

    Article  CAS  PubMed  Google Scholar 

  116. Bunin GR, et al. Neuroblastoma and parental occupation. Am J Epidemiol. 1990;131(5):776–80.

    CAS  PubMed  Google Scholar 

  117. Strenger V, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer. 2007;48(5):504–9.

    Article  PubMed  Google Scholar 

  118. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45(7):1172–88.

    PubMed  Google Scholar 

  120. Olivier P, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30(5):B45–50.

    Article  PubMed  Google Scholar 

  121. Lonergan GJ, et al. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002;22(4):911–34.

    Article  PubMed  Google Scholar 

  122. Howman-Giles RB, Gilday DL, Ash JM. Radionuclide skeletal survey in neuroblastoma. Radiology. 1979;131(2):497–502.

    Article  CAS  PubMed  Google Scholar 

  123. Sharp SE, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237–43.

    Article  PubMed  Google Scholar 

  124. Choi YJ, et al. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Ann Nucl Med. 2014;28(4):304–13.

    Article  PubMed  Google Scholar 

  125. Taggart DR, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27(32):5343–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Piccardo A, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39(1):57–71.

    Article  CAS  PubMed  Google Scholar 

  127. Pashankar FD, O’Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med. 2005;46 Suppl 1:55S–61.

    CAS  PubMed  Google Scholar 

  128. Kroiss A, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification. Eur J Nucl Med Mol Imaging. 2012;39(3):543.

    Article  PubMed  Google Scholar 

  129. De Krijger RR, et al. Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci. 2006;1073:166–76.

    Article  PubMed  CAS  Google Scholar 

  130. Pacak K, et al. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med. 2005;257(1):60–8.

    Article  CAS  PubMed  Google Scholar 

  131. Pacak K, Eisenhofer G, Grossman A. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(19):2005.

    Article  CAS  PubMed  Google Scholar 

  132. Pacak K, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102.

    Article  PubMed  Google Scholar 

  133. Havekes B, et al. Update on pediatric pheochromocytoma. Pediatr Nephrol. 2009;24(5):943–50.

    Article  PubMed  Google Scholar 

  134. Trampal C, et al. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004;230(2):423–8.

    Article  PubMed  Google Scholar 

  135. Janssen I, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Brugieres L, Minard V, Patte C. Lymphomas in children and adolescents. Rev Prat. 2012;62(4):453–8.

    PubMed  Google Scholar 

  137. Bhatia S, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386–94.

    Article  PubMed  Google Scholar 

  138. Prasad PK, et al. Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer. 2012;58(3):421–7.

    Article  PubMed  Google Scholar 

  139. Howman-Giles R, Stevens M, Bergin M. Role of gallium-67 in management of paediatric solid tumours. Aust Paediatr J. 1982;18(2):120–5.

    CAS  PubMed  Google Scholar 

  140. Sty JR, Kun LE, Starshak RJ. Pediatric applications in nuclear oncology. Semin Nucl Med. 1985;15(2):171–200.

    Article  CAS  PubMed  Google Scholar 

  141. Elstrom R, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10):3875–6.

    Article  CAS  PubMed  Google Scholar 

  142. Rigacci L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol. 2007;86(12):897–903.

    Article  PubMed  Google Scholar 

  143. Jerusalem G, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86(3):266–73.

    CAS  PubMed  Google Scholar 

  144. London K, et al. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging. 2011;38(2):274–84.

    Article  PubMed  Google Scholar 

  145. Hutchings M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006;91(4):482–9.

    PubMed  Google Scholar 

  146. Kabickova E, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2006;33(9):1025–31.

    Article  PubMed  Google Scholar 

  147. Moulin-Romsee G, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37(6):1095–105.

    Article  PubMed  Google Scholar 

  148. Pelosi E, et al. FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging. 2008;52(1):9–16.

    CAS  PubMed  Google Scholar 

  149. Purz S, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2011;29(26):3523–8.

    Article  PubMed  Google Scholar 

  150. Girinsky T, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol. 2007;85(2):178–86.

    Article  PubMed  Google Scholar 

  151. Hermann S, et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin. 2005;44(1):1–7.

    CAS  PubMed  Google Scholar 

  152. Muslimani AA, et al. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol. 2008;31(5):409–12.

    Article  PubMed  Google Scholar 

  153. Kluge R, et al. FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol. 2013;43(4):406–17.

    Article  PubMed  Google Scholar 

  154. Weiler-Sagie M, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.

    Article  PubMed  Google Scholar 

  155. Abramson SJ, Price AP. Imaging of pediatric lymphomas. Radiol Clin North Am. 2008;46(2):313–38, ix.

    Article  PubMed  Google Scholar 

  156. Toma P, et al. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics. 2007;27(5):1335–54.

    Article  PubMed  Google Scholar 

  157. Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  158. Cahu X, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol. 2011;22(3):705–11.

    Article  CAS  PubMed  Google Scholar 

  159. Karantanis D, et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol. 2010;75(1):e68–73.

    Article  PubMed  Google Scholar 

  160. Rini JN, et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44(7):1072–4.

    PubMed  Google Scholar 

  161. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–16.

    Article  CAS  PubMed  Google Scholar 

  162. Rhodes MM, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28(5):300–6.

    Article  PubMed  Google Scholar 

  163. Furth C, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27(26):4385–91.

    Article  PubMed  Google Scholar 

  164. Kostakoglu L, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43(8):1018–27.

    PubMed  Google Scholar 

  165. Kluge R, Korholz D. Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Padiatr. 2011;223(6):315–9.

    Article  CAS  PubMed  Google Scholar 

  166. Radford J, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607.

    Article  CAS  PubMed  Google Scholar 

  167. Duhrsen U, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial. Leuk Lymphoma. 2009;50(11):1757–60.

    Article  PubMed  Google Scholar 

  168. Depas G, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging. 2005;32(1):31–8.

    Article  PubMed  Google Scholar 

  169. Bakhshi S, et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. Radiology. 2012;262(3):956–68.

    Article  PubMed  Google Scholar 

  170. Lavely WC, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(2):307–15.

    Article  PubMed  Google Scholar 

  171. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev. 2004;18(3):193–209.

    Article  PubMed  Google Scholar 

  172. Blaes AH, Morrison VA. Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol. 2010;3(1):35–44.

    Article  PubMed  Google Scholar 

  173. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155–67.

    Article  PubMed  Google Scholar 

  174. Feng S, et al. Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant. 2003;3(12):1481–7.

    Article  PubMed  Google Scholar 

  175. Dharnidharka VR, et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2(10):993–8.

    Article  PubMed  Google Scholar 

  176. Shapiro R, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999;68(12):1851–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Leblond V, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. 1995;13(4):961–8.

    CAS  PubMed  Google Scholar 

  178. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–30.

    Article  PubMed  Google Scholar 

  179. Gallego S, et al. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab. Pediatr Transplant. 2010;14(1):61–6.

    Article  CAS  PubMed  Google Scholar 

  180. Campo E, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  181. Bianchi E, et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation. 2008;85(5):707–12.

    Article  PubMed  Google Scholar 

  182. Dierickx D, et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica. 2013;98(5):771–5.

    Article  PubMed  PubMed Central  Google Scholar 

  183. O’Conner AR, Franc BL. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation. Nucl Med Commun. 2005;26(12):1107–11.

    Article  PubMed  Google Scholar 

  184. Takehana CS, et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nucl Med Commun. 2014;35(3):276–81.

    Article  PubMed  Google Scholar 

  185. Bakker NA, et al. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006;6(8):1984–5.

    Article  CAS  PubMed  Google Scholar 

  186. Noraini AR, et al. PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation. Singapore Med J. 2009;50(12):1189–95.

    CAS  PubMed  Google Scholar 

  187. Panagiotidis E, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2014;55(3):515–9.

    Article  PubMed  Google Scholar 

  188. von Falck C, et al. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol. 2007;63(3):427–35.

    Article  Google Scholar 

  189. Su K, et al. Diffuse homogeneous bone marrow uptake of FDG in patients with acute lymphoblastic leukemia. Clin Nucl Med. 2013;38(1):e33–4.

    Article  PubMed  Google Scholar 

  190. Endo T, et al. Localized relapse in bone marrow of extremities after allogeneic stem cell transplantation for acute lymphoblastic leukemia. Am J Hematol. 2004;76(3):279–82.

    Article  CAS  PubMed  Google Scholar 

  191. Sharp SE, Gelfand MJ, Absalon MJ. Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids. Pediatr Radiol. 2012;42(3):331–6.

    Article  PubMed  Google Scholar 

  192. Stanescu L, et al. FDG PET of the brain in pediatric patients: imaging spectrum with MR imaging correlation. Radiographics. 2013;33(5):1279–303.

    Article  PubMed  Google Scholar 

  193. Kruer MC, et al. The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood. J Neurooncol. 2009;95(2):239–45.

    Article  PubMed  Google Scholar 

  194. Borgwardt L, et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol. 2005;23(13):3030–7.

    Article  PubMed  Google Scholar 

  195. Glantz MJ, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991;29(4):347–55.

    Article  CAS  PubMed  Google Scholar 

  196. Hanson MW, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr. 1991;15(5):796–801.

    Article  CAS  PubMed  Google Scholar 

  197. Giovannini E, et al. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21(1):121–7.

    Article  CAS  PubMed  Google Scholar 

  198. Torii K, et al. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med. 2005;19(8):677–83.

    Article  PubMed  Google Scholar 

  199. Ceyssens S, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27(7):1432–7.

    CAS  PubMed  Google Scholar 

  200. Van Laere K, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  201. Hipp SJ, et al. Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using (1)(8)F-FDG-PET and MRSI. J Neurooncol. 2012;109(3):521–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Gilday DL, Ash JM, Reilly BJ. Radionuclide skeletal survey for pediatric neoplasms. Radiology. 1977;123(2):399–406.

    Article  CAS  PubMed  Google Scholar 

  203. Rosen G, et al. Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy. Clin Orthop Relat Res. 1993;293:302–6.

    Google Scholar 

  204. Ramanna L, et al. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med. 1990;31(5):567–72.

    CAS  PubMed  Google Scholar 

  205. Volker T, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25(34):5435–41.

    Article  PubMed  Google Scholar 

  206. Byun BH, et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skeletal Radiol. 2013;42(12):1673–81.

    Article  PubMed  Google Scholar 

  207. Huang TL, et al. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. J Chin Med Assoc. 2006;69(8):372–6.

    Article  PubMed  Google Scholar 

  208. Mansky PJ, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 2002;24(6):440–6.

    Article  PubMed  Google Scholar 

  209. Kong CB, et al. (1)(8)F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging. 2013;40(5):728–36.

    Article  CAS  PubMed  Google Scholar 

  210. Erlemann R, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175(3):791–6.

    Article  CAS  PubMed  Google Scholar 

  211. Gaston LL, et al. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol. 2011;40(8):1007–15.

    Article  PubMed  Google Scholar 

  212. Tateishi U, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med. 2009;23(2):155–61.

    Article  PubMed  Google Scholar 

  213. Klem ML, et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol. 2007;29(1):9–14.

    Article  PubMed  Google Scholar 

  214. Adler LP, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32(8):1508–12.

    CAS  PubMed  Google Scholar 

  215. Ricard F, et al. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med. 2011;36(8):672–7.

    Article  PubMed  Google Scholar 

  216. Moinul Hossain AK, et al. FDG positron emission tomography/computed tomography studies of Wilms’ tumor. Eur J Nucl Med Mol Imaging. 2010;37(7):1300–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Qin Z, et al. Use of 18F-FDG-PET-CT for assessment of response to neoadjuvant chemotherapy in children with Wilms tumor. J Pediatr Hematol Oncol. 2015;37:396–401.

    Article  CAS  PubMed  Google Scholar 

  218. Wong KK, et al. The use of positron emission tomography in detecting hepatoblastoma recurrence--a cautionary tale. J Pediatr Surg. 2004;39(12):1779–81.

    Article  PubMed  Google Scholar 

  219. Mody RJ, et al. FDG PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer. 2006;47(1):51–5.

    Article  PubMed  Google Scholar 

  220. Ciarallo A, et al. Value of fluorodeoxyglucose PET/computed tomography patient management and outcomes in thyroid cancer. PET Clin. 2015;10(2):265–78.

    Article  PubMed  Google Scholar 

  221. Asa S, et al. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Ann Nucl Med. 2014;28(10):970–9.

    Article  CAS  PubMed  Google Scholar 

  222. Elboga U, et al. F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience. Eur Rev Med Pharmacol Sci. 2015;19(3):396–401.

    CAS  PubMed  Google Scholar 

  223. Beheshti M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19(6):1425–34.

    Article  PubMed  Google Scholar 

  224. Howe TC, et al. Role of Tc-99m DMSA (V) scanning and serum calcitonin monitoring in the management of medullary thyroid carcinoma. Singapore Med J. 2008;49(1):19–22.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint Michael Hospital, University of Toronto, Toronto, ON, Canada

    Joe Barfett

  2. The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Reza Vali & Amer Shammas

Authors
  1. Joe Barfett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Vali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amer Shammas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amer Shammas .

Editor information

Editors and Affiliations

  1. Medical Biophysics Department of Physics Faculty of Science, Helwan University, Cairo, Egypt

    Magdy M. Khalil

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barfett, J., Vali, R., Shammas, A. (2017). Role of PET/CT in Pediatric Malignancy. In: Khalil, M. (eds) Basic Science of PET Imaging. Springer, Cham. https://doi.org/10.1007/978-3-319-40070-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40070-9_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40068-6

  • Online ISBN: 978-3-319-40070-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation